PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
18.43%
Some net income increase while TRVN is negative at -8.68%. John Neff would see a short-term edge over the struggling competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.55%
Both cut yoy SBC, with TRVN at -14.03%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
69.28%
Well above TRVN's 94.63% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
AP growth well above TRVN's 100.00%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-92.45%
Negative yoy usage while TRVN is 31.20%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
109.32%
Some yoy increase while TRVN is negative at -5.49%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
22.94%
Operating cash flow growth above 1.5x TRVN's 14.43%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.52%
We cut debt repayment yoy while TRVN is 99.94%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1850.82%
Stock issuance far above TRVN's 801.97%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.